Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Infinity Pharmaceuticals, Inc. (NASDAQ: INFI).

Full DD Report for INFI

You must become a subscriber to view this report.


Recent News from (NASDAQ: INFI)

Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2018 Results - Earnings Call Transcript
Infinity Pharmaceuticals, Inc. (INFI) Q3 2018 Earnings Conference Call November 5, 2018 4:30 PM ET Executives Jayne Kauffman – Senior Executive Coordinator Adelene Perkins – Chief Executive Officer Larry Bloch – President Sam Agresta – Chief Medical ...
Source: SeekingAlpha
Date: November, 05 2018 21:43
Infinity Pharmaceuticals beats by $0.36
Infinity Pharmaceuticals (NASDAQ: INFI ): Q3 GAAP EPS of $0.23 beats by $0.36 . More news on: Infinity Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Consumer stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 16:24
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results
CAMBRIDGE, Mass. , Nov. 5, 2018 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that s...
Source: PR Newswire
Date: November, 05 2018 16:03
Infinity Pharma teams up with Bristol-Myers Squibb in urothelial cancer
Bristol-Myers Squibb (NYSE: BMY ) and Infinity Pharmaceuticals (NASDAQ: INFI ) will collaborate on a clinical trial evaluating the combination of Opdivo (nivolumab) and IPI-549, a PI3K-gamma inhibitor, in patients with advanced urothelial cancer who have progressed after platinum-based che...
Source: SeekingAlpha
Date: November, 05 2018 08:18
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19-- Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combinati...
Source: Business Wire
Date: November, 05 2018 06:59
Infinity Announces IPI-549 Late-Breaking Presentation at SITC 33rd Annual Meeting
CAMBRIDGE, Mass. , Nov. 1, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that an abstract describing data from the expansion of the MARIO-1 Phase 1b Study of IPI-549 in combination with nivolumab in advanced solid tumors has been selected as a late-b...
Source: PR Newswire
Date: November, 01 2018 14:23
Infinity Announces the Date of Its Third Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 29, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Monday, November 5, 2018 , at 4:30 p.m. ET to review its third quarter 2018 financial results and provide an update on the company. A live webcast...
Source: PR Newswire
Date: October, 29 2018 08:32
Week 37 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 37: Market conditions have generated a slight decrease in positive breakout momentum and a strong increase in negative momentum this week. The positive momentum gauge moved lower to 44, down from a value of 65 at the end of last week. The yellow positi...
Source: SeekingAlpha
Date: September, 09 2018 23:56
Infinity To Present At Three Upcoming Investor Conferences In September
CAMBRIDGE, Mass. , Aug. 28, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceuticals' Chief Executive Officer, and Lawrence Bloch , Infinity Pharmaceuticals' President, will present at the following conferenc...
Source: PR Newswire
Date: August, 28 2018 08:32
Research Report Identifies America's Car-Mart, SAExploration, Ascena Retail Group, Infinity Pharmaceuticals, Hologic, and California Resources with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of America's Car-Mart, Inc. (NASDAQ:CRMT), SAExploration Holdings, Inc. (NAS...
Source: GlobeNewswire
Date: August, 22 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-071.251.28921.321.24273,332
2018-12-061.251.2451.281.20715,160
2018-12-051.301.211.361.21469,819
2018-12-041.301.211.361.21391,420
2018-12-031.391.331.391.32332,030

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0735,52871,11549.9585Short
2018-12-06104,131209,12249.7944Short
2018-12-0492,486170,02254.3965Short
2018-12-0332,924114,85128.6667Cover
2018-11-309,92454,23418.2985Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INFI.


About Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

Logo for Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

Not available

 

Contact Information

 

 

Current Management

  • Adelene Q. Perkins / EVP, CBO

Current Share Structure

  • Market Cap: $108,080,544 - 05/16/2018
  • Issue and Outstanding: 51,961,800 - 03/01/2018

 



Daily Technical Chart for (NASDAQ: INFI)

Daily Technical Chart for (NASDAQ: INFI)


Stay tuned for daily updates and more on (NASDAQ: INFI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INFI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INFI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INFI and does not buy, sell, or trade any shares of INFI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/